<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04430699</url>
  </required_header>
  <id_info>
    <org_study_id>20-109</org_study_id>
    <nct_id>NCT04430699</nct_id>
  </id_info>
  <brief_title>Cisplatin+Pembrolizumab+RT in Vulvar Cancer</brief_title>
  <official_title>A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to see how well the combination of a standard of care drug,&#xD;
      investigational drug, and radiation therapy work against unresectable vulvar squamous cell&#xD;
      carcinoma.&#xD;
&#xD;
      This research study involves the following:&#xD;
&#xD;
        -  Cisplatin (standard of care drug)&#xD;
&#xD;
        -  Pembrolizumab (investigational drug)&#xD;
&#xD;
        -  Radiation Therapy (standard of care intervention)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm phase 2 clinical trial involving women with unresectable, incompletely&#xD;
      resected, recurrent, or metastatic vulva squamous cell carcinoma. This study combines&#xD;
      cisplatin, pembrolizumab, and radiation therapy to see if this combination further increases&#xD;
      participants' immune system's efficiency in killing their tumor, and if the combination&#xD;
      decreases the chances of participants' cancer coming back.&#xD;
&#xD;
      The research study procedures include screening for eligibility and study treatment including&#xD;
      evaluations and follow up visits.&#xD;
&#xD;
      This research study involves the following:&#xD;
&#xD;
        -  Cisplatin (standard of care drug)&#xD;
&#xD;
        -  Pembrolizumab (investigational drug)&#xD;
&#xD;
        -  Radiation Therapy (standard of care intervention)&#xD;
&#xD;
      Participants will receive study treatment for up to 36 weeks and will be followed for up to 3&#xD;
      years.&#xD;
&#xD;
      It is expected that about 24 people will take part in this research study.&#xD;
&#xD;
      Phase II clinical trials test the safety and effectiveness of an investigational drug to&#xD;
      learn whether the drug works in treating a specific disease. &quot;Investigational&quot; means that the&#xD;
      drug is being studied. The U.S. Food and Drug Administration (FDA) has approved cisplatin as&#xD;
      a treatment option for vulva squamous cell carcinoma. The FDA has not approved pembrolizumab&#xD;
      for vulva squamous cell carcinoma, but it has been approved for other uses. Cisplatin is a&#xD;
      chemotherapy drug and will be given to participants per standard of care.&#xD;
&#xD;
      Radiation therapy will be given to you per standard of care. Pembrolizumab is a drug that may&#xD;
      target participants immune systems to increase its efficiency in targeting and killing&#xD;
      illnesses and diseases, such as unresectable vulvar squamous cell carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>To determine the Overall response rate (ORR) in patients undergoing combination therapy with pembrolizumab and cisplatin-sensitized external beam radiation therapy by RECIST 1.1 criteria.&#xD;
This sample size calculation is based on an ORR of greater than or equal to 60%. For recurrent metastatic disease, there are is no standard of care.The ORR estimation is informed by data showing an ORR of 40% in patients with advanced or recurrent metastatic vulvar cancer treated with platinum-based combination therapy. Singleagent chemotherapy has an ORR of about 12% (5). Patients with primary disease who are not candidates for upfront surgery have a reported response rates from 55% to 64%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival (RFS)-6 months</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the 6-month Recurrence Free Survival (RFS) in patients with locally advanced, unresectable, or recurrent metastatic vulvar cancer treated with concurrent cisplatin-sensitized radiation therapy and pembrolizumab. A point estimate with exact 95% CI and Kaplan-Meier estimate will be used for the RFS distribution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Vulvar Cancer</condition>
  <condition>Vulvar Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab, Cisplatin and Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period is 36 weeks with 21 day study cycles.&#xD;
Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.&#xD;
First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.&#xD;
Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.</description>
    <arm_group_label>Pembrolizumab, Cisplatin and Radiation Therapy</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.</description>
    <arm_group_label>Pembrolizumab, Cisplatin and Radiation Therapy</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Standard of care radiation therapy 1x daily up to 8 weeks.</description>
    <arm_group_label>Pembrolizumab, Cisplatin and Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have histologically or cytologically confirmed unresectable,&#xD;
             incompletely resected, recurrent, or metastatic squamous cell carcinoma of the&#xD;
             vulva.Patients with unresectable disease are defined as T2 or T3 primary tumors (N0-3,&#xD;
             M0) not amenable to surgical resection by standard radical vulvectomy.&#xD;
&#xD;
          -  Participants must have measurable disease based on RECIST 1.1. Lesions situated in a&#xD;
             previously irradiated area are considered measurable if progression has been&#xD;
             demonstrated in such lesions.&#xD;
&#xD;
          -  Have provided archival tumor tissue sample or newly obtained core or excisional biopsy&#xD;
             of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE)&#xD;
             tissue blocks are preferred to slides.&#xD;
&#xD;
          -  Prior therapy: Participants with no prior therapy are eligible and patients with&#xD;
             recurrent disease must not have had more than two lines of cytotoxic therapy. Topical&#xD;
             or hormonal therapy are not counted towards prior lines. Prior treatment with&#xD;
             immunotherapy is allowed, provided treatment was not stopped for grade 2 or greater&#xD;
             adverse events.&#xD;
&#xD;
          -  Time from prior therapy:&#xD;
&#xD;
               -  Systemic anti-neoplastic therapy: 5 half-lives or 4 weeks, whichever is shorter.&#xD;
&#xD;
               -  Hormonal therapy is not considered anti-neoplastic therapy.&#xD;
&#xD;
               -  Radiotherapy: Any prior irradiation is acceptable provided the site being&#xD;
                  considered for study has not been previously irradiated.&#xD;
&#xD;
          -  Age ≥18 years. Because insufficient dosing or adverse event data are currently&#xD;
             available on the use of pembrolizumab in combination with cisplatin-sensitized&#xD;
             radiation therapy participants &lt;18 years of age, children are excluded. Vulva cancer&#xD;
             is rare in the pediatric population&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Participants must have adequate organ and marrow function as defined below (Table 1):&#xD;
&#xD;
               -  Table 1: Adequate Organ Function Laboratory Values&#xD;
&#xD;
                    -  Hematological&#xD;
&#xD;
                         -  Absolute neutrophil count (ANC) ≥1500/μL&#xD;
&#xD;
                         -  Platelets ≥100 000/μL&#xD;
&#xD;
                         -  Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La&#xD;
&#xD;
                    -  Renal&#xD;
&#xD;
                         -  Creatinine OR Measured or calculated b creatinine clearance (GFR can&#xD;
                            also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥50 mL/min&#xD;
                            for participant with creatinine&#xD;
&#xD;
                    -  Hepatic&#xD;
&#xD;
                         -  Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants&#xD;
                            with total bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
                         -  AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with&#xD;
                            liver metastases)&#xD;
&#xD;
                    -  Coagulation&#xD;
&#xD;
                         -  International normalized ratio (INR) OR prothrombin time (PT) Activated&#xD;
                            partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is&#xD;
                            receiving anticoagulant therapy as long as PT or aPTT is within&#xD;
                            therapeutic range of intended use of anticoagulants&#xD;
&#xD;
                         -  ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic&#xD;
                            transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic&#xD;
                            oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper&#xD;
                            limit of normal.&#xD;
&#xD;
                         -  Criteria must be met without erythropoietin dependency and without&#xD;
                            packed red blood cell (pRBC) transfusion within last 2 weeks.&#xD;
&#xD;
                         -  Creatinine clearance (CrCl) should be calculated per institutional&#xD;
                            standard.&#xD;
&#xD;
                         -  Note: This table includes eligibility-defining laboratory value&#xD;
                            requirements for treatment; laboratory value requirements should be&#xD;
                            adapted according to local regulations and guidelines for the&#xD;
                            administration of specific chemotherapies.&#xD;
&#xD;
          -  Participant must be female, and is eligible to participate if she is not pregnant (see&#xD;
             Appendix B), not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR&#xD;
&#xD;
               -  A WOCBP must agree to use adequate contraception (hormonal or barrier method of&#xD;
                  birth control; abstinence) prior to study entry, during study treatment, and for&#xD;
                  at least twelve weeks after the last dose of study treatment. Should a woman&#xD;
                  become pregnant or suspect she is pregnant while she is pregnant while she is&#xD;
                  participating in this study, she should inform her treating physician&#xD;
                  immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who in the opinion of the investigator cannot safely receive a minimum of 30&#xD;
             Gy in 10 fractions are not eligible for the trial.&#xD;
&#xD;
          -  Participants who have received prior systemic anti-cancer therapy including&#xD;
             investigational agents within 4 weeks prior to first dose of study treatment. Note: If&#xD;
             participant received major surgery, they must have recovered adequately from the&#xD;
             toxicity and/or complications from the intervention prior to starting study treatment&#xD;
&#xD;
          -  Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or&#xD;
             baseline.&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. Re-irradiation to a&#xD;
             previously treated site will not be permitted.&#xD;
&#xD;
          -  Participants who have received a live vaccine within 30 days prior to the first dose&#xD;
             of study drug. Examples of live vaccines include, but are not limited to, the&#xD;
             following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever,&#xD;
             rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza&#xD;
             vaccines for injection are generally killed virus vaccines and are allowed; however,&#xD;
             intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not&#xD;
             allowed.&#xD;
&#xD;
          -  Participants with vulvar melanomas, sarcomas, extramammary Paget's disease, or basal&#xD;
             cell carcinoma&#xD;
&#xD;
          -  Participants with a history of gastrointestinal or colovesicular fistulae&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has known active CNS metastases and/or carcinomatous meningitis. Participants with&#xD;
             previously treated brain metastases may participate provided they are radiologically&#xD;
             stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging&#xD;
             (note that the repeat imaging should be performed during study screening), clinically&#xD;
             stable and without requirement of steroid treatment for at least 14 days prior to&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Patients with a history of other invasive malignancies, with the exception of&#xD;
             nonmelanoma skin cancer, are excluded if there is any evidence of other malignancy&#xD;
             being present within the last five years. Patients are also excluded if their previous&#xD;
             cancer treatment contraindicates this protocol therapy.&#xD;
&#xD;
          -  Participants with uncontrolled intercurrent illness.&#xD;
&#xD;
          -  Participants with psychiatric illness/social situations that would limit compliance&#xD;
             with study requirements.&#xD;
&#xD;
          -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is&#xD;
             detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required.&#xD;
&#xD;
          -  Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
          -  Pregnant or nursing women are excluded from this study because effects of agents used&#xD;
             in this study on infants or the developing human fetus are unknown.&#xD;
&#xD;
          -  Presence of other malignancies unless they are considered cured by patient's&#xD;
             oncologist.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oladapo Yeku, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oladapo Yeku, MD, PHD</last_name>
    <phone>617-643-9354</phone>
    <email>oyeku@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oladapo Yeku, MD, PhD</last_name>
      <phone>617-643-9354</phone>
      <email>oyeku@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Oladapo Yeku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yeku O, Russo AL, Lee H, Spriggs D. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med. 2020 Sep 14;18(1):350. doi: 10.1186/s12967-020-02523-5.</citation>
    <PMID>32928237</PMID>
  </reference>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>April 4, 2022</last_update_submitted>
  <last_update_submitted_qc>April 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Oladapo O. Yeku,M.D.,Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vulvar Cancer</keyword>
  <keyword>Vulvar Squamous Cell Carcinoma,</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Radiation</keyword>
  <keyword>Pembrolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication.</ipd_time_frame>
    <ipd_access_criteria>Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04430699
org study id: 20-109
nct id: NCT04430699
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This research is being done to see how well the combination of a standard of care drug,
      investigational drug, and radiation therapy work against unresectable vulvar squamous cell
      carcinoma.

      This research study involves the following:

        -  Cisplatin (standard of care drug)

        -  Pembrolizumab (investigational drug)

        -  Radiation Therapy (standard of care intervention)
This is a single-arm phase 2 clinical trial involving women with unresectable, incompletely
      resected, recurrent, or metastatic vulva squamous cell carcinoma. This study combines
      cisplatin, pembrolizumab, and radiation therapy to see if this combination further increases
      participants' immune system's efficiency in killing their tumor, and if the combination
      decreases the chances of participants' cancer coming back.

      The research study procedures include screening for eligibility and study treatment including
      evaluations and follow up visits.

      This research study involves the following:

        -  Cisplatin (standard of care drug)

        -  Pembrolizumab (investigational drug)

        -  Radiation Therapy (standard of care intervention)

      Participants will receive study treatment for up to 36 weeks and will be followed for up to 3
      years.

      It is expected that about 24 people will take part in this research study.

      Phase II clinical trials test the safety and effectiveness of an investigational drug to
      learn whether the drug works in treating a specific disease. "Investigational" means that the
      drug is being studied. The U.S. Food and Drug Administration (FDA) has approved cisplatin as
      a treatment option for vulva squamous cell carcinoma. The FDA has not approved pembrolizumab
      for vulva squamous cell carcinoma, but it has been approved for other uses. Cisplatin is a
      chemotherapy drug and will be given to participants per standard of care.

      Radiation therapy will be given to you per standard of care. Pembrolizumab is a drug that may
      target participants immune systems to increase its efficiency in targeting and killing
      illnesses and diseases, such as unresectable vulvar squamous cell carcinoma.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Overall response rate (ORR)
time frame: Up to 36 weeks
description: To determine the Overall response rate (ORR) in patients undergoing combination therapy with pembrolizumab and cisplatin-sensitized external beam radiation therapy by RECIST 1.1 criteria.
This sample size calculation is based on an ORR of greater than or equal to 60%. For recurrent metastatic disease, there are is no standard of care.The ORR estimation is informed by data showing an ORR of 40% in patients with advanced or recurrent metastatic vulvar cancer treated with platinum-based combination therapy. Singleagent chemotherapy has an ORR of about 12% (5). Patients with primary disease who are not candidates for upfront surgery have a reported response rates from 55% to 64%.
measure: Recurrence Free Survival (RFS)-6 months
time frame: 6 months
description: To determine the 6-month Recurrence Free Survival (RFS) in patients with locally advanced, unresectable, or recurrent metastatic vulvar cancer treated with concurrent cisplatin-sensitized radiation therapy and pembrolizumab. A point estimate with exact 95% CI and Kaplan-Meier estimate will be used for the RFS distribution.
arm group label: Pembrolizumab, Cisplatin and Radiation Therapy
arm group type: Experimental
description: Treatment period is 36 weeks with 21 day study cycles.
Participants will receive cisplatin at a predetermined dose 1x weekly, pembrolizumab at a predetermined dose every 3 weeks, concurrently with daily radiation therapy from week 1 up to week 8.
First 3 participants on the study, may skip 1 or 2 pembrolizumab dosages while receiving radiation therapy.
Following completion of daily radiation therapy with 1x weekly cisplatin and 1x every 3 weeks pembrolizumab, participants will continue at a pre-determined maintenance dose of pembrolizumab 1x every 3 weeks for a total of 12 cycles or 36 weeks.
intervention type: Drug
intervention name: Cisplatin
description: Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.
arm group label: Pembrolizumab, Cisplatin and Radiation Therapy
other name: Platinol
other name: Platinol-AQ
other name: CDDP
intervention type: Drug
intervention name: Pembrolizumab
description: Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.
arm group label: Pembrolizumab, Cisplatin and Radiation Therapy
other name: Keytruda
intervention type: Radiation
intervention name: Radiation Therapy
description: Standard of care radiation therapy 1x daily up to 8 weeks.
arm group label: Pembrolizumab, Cisplatin and Radiation Therapy
criteria: 
gender: Female
gender based: Yes
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Oladapo Yeku, MD, PHD
role: Principal Investigator
affiliation: Massachusetts General Hospital
last name: Oladapo Yeku, MD, PHD
phone: 617-643-9354
email: oyeku@mgh.harvard.edu
facility: 
status: Recruiting
contact: 
investigator: 
country: United States
citation: Yeku O, Russo AL, Lee H, Spriggs D. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J Transl Med. 2020 Sep 14;18(1):350. doi: 10.1186/s12967-020-02523-5.
PMID: 32928237
responsible party type: Principal Investigator
investigator affiliation: Massachusetts General Hospital
investigator full name: Oladapo O. Yeku,M.D.,Ph.D.
investigator title: Principal Investigator
mesh term: Carcinoma
mesh term: Carcinoma, Squamous Cell
mesh term: Vulvar Neoplasms
mesh term: Cisplatin
mesh term: Pembrolizumab
sharing ipd: Yes
ipd description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
ipd info type: Study Protocol
ipd info type: Statistical Analysis Plan (SAP)
ipd info type: Informed Consent Form (ICF)
ipd time frame: Data can be shared no earlier than 1 year following the date of publication.
ipd access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation